Health Update: Health Update: Genvor Announces Strategic Expansion into Health and Wellness Market, Leveraging Proprietary AI-Accelerated BioCypher Platform to Develop Consumer Peptide Solutions – What Experts Say– What Experts Say.
Company’s proprietary peptide platform expands beyond agriculture into human recovery, performance, and wellness
Woodland, CA, March 04, 2026 (GLOBE NEWSWIRE) — Genvor, Inc. (OTCQB: GNVR), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health, today announced its formal entry into the human health and wellness sector, marking a significant expansion of its corporate strategy into consumer-focused biological innovation.
The expansion is powered by Genvor’s proprietary BioCypher platform, an AI-driven peptide generation engine backed by a library of millions of designed peptides that has already produced dozens of researched lead agricultural candidates across more than a dozen pathogens and multiple areas of crop protection. With health and wellness peptides already engineered within this library, Genvor is now leveraging the BioCypher platform to identify and advance the most promising candidates into safe, effective, and commercially viable consumer health and wellness products.
With global peptide therapeutics and supplements markets experiencing strong growth and projected to reach multi-billion-dollar valuations in the coming decade, Genvor is positioned to apply its deep scientific expertise and proven peptide design capabilities to meet surging consumer demand for science-backed recovery, performance, and wellness solutions. Industry analysts forecast the global peptide supplements market alone to grow from approximately USD $4.1 billion in 2025 to USD $11.2 billion by 2035, driven by rising consumer interest in muscle recovery, immune support, and bioavailable health products.
“Our BioCypher platform has already demonstrated its power across more than a dozen agricultural pathogens and multiple meaningful areas of crop protection,” said Chad Pawlak, Chief Executive Officer of Genvor. “Expanding into consumer health and wellness reflects our ability to unlock what has been in our library since the company’s founding. Advancing these product candidates into consumer markets is a natural evolution that creates multiple revenue pathways from a single platform. This expansion positions us to innovate responsibly while delivering meaningful value to customers, commercial partners and investors.”
Genvor’s BioCypher platform combines computational biology with machine learning to generate novel peptides faster than traditional R&D approaches, designing candidates optimized for both agricultural performance and human bioavailability. The company’s dual-market commercialization model pairs a licensing-first approach in agriculture with a direct-to-consumer model in human health, bringing targeted peptide-based recovery and performance solutions to market through strategic partnerships and retail channels.